上海复宏汉霖生物技术股份有限公司 Henlius
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population 2021-12-20 22:00
Henlius' Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint 2021-12-08 08:30
Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration 2021-12-04 01:51
Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia 2021-11-25 17:27
2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar 2021-09-18 20:00
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint 2021-09-17 20:00
Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation 2021-08-18 21:35
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review 2021-04-23 15:00
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review 2021-04-22 21:47
Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint 2021-03-29 08:27
Making Most out of Launched Products Fueling Diversified Innovation through Integrated Platform 2021-03-28 11:16
Henlius Adalimumab Biosimilar Approved by NMPA 2020-12-08 21:00
China's First Trastuzumab Biosimilar Approved by NMPA 2020-08-17 08:00
Henlius and Accord Healthcare Receive EMA Approval for Zercepac®, trastuzumab biosimilar 2020-07-30 08:00
Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab) 2020-06-01 13:48
Henlius receives EU GMP Certificate for HLX02 (Trastuzumab for Injection) 2020-04-23 22:02
Henlius successfully held its fourth Scientific Advisory Board (SAB) meeting 2020-02-18 21:59
Henlius HLX01 (Rituximab Injection) Wins "Biosimilar Initiative of the Year" at Global Generics & Biosimilars Awards 2019 2019-11-07 01:00
European Medicines Agency Accepted First "China-Developed" Biosimilar - Henlius HLX02 Marketing Authorization Application for Review 2019-06-21 20:29
1 2 3